About

About Syncromune Syncromune is a clinical-stage biopharmaceutical company that is developing the SYNC-T platform immunotherapy for advance solid tumor cancers, with initial focus on metastatic castration-resistant prostate cancer mCRPC). SYNC-T is a novel personalized combination immunotherapy that is performed completely in situ. It is designed to synchronize the location of key components necessary to create a systemic anti-tumor response within the lymphatic system: patient-specific tumor antigens, our multi-target drug, and immune cells. Using a dual-function device delivery system, it first uses partial cryolysis of a target tumor to release the patient’s own tumor antigens. Then, through the same device, SV-102, a multi-target immunotherapeutic consisting of four immune modulators is infused into the zone of cryolysis. The volume of the infusion then promotes drainage of the tumor antigens and SV-102 into regional lymph nodes where they synchronize location with immune cells. Co-localizing these three components can then empower the immune system to activate T cells and mount a systemic anti-tumor response against both primary and metastatic lesions. Our lead candidate SYNC-T Therapy SV-102 is currently being evaluated in the LEGION-100, a Phase 2 trial for mCRPC. To learn more visit www.legion100trial.com or www.syncromune.com.